Your browser does not support JavaScript or it may be disabled!
rediff.com
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
NEWS ON MOBILE
Get Realtime News
on your webpage

About 853 results for "novartis"

Novartis: Interim Data Shows Potential Of GP2013 As Alternative Rituximab
Nasdaq

Novartis' Zykadia beats chemo in late-stage lung cancer study

Results from an open-label Phase 3 study, ASCEND-4, evaluating Novartis' (NYSE: NVS ) Zykadia (ceritinib) for the first-line treatment of patients with anaplastic lymphoma kinase-positive (ALK+) advanced non-small cell lung cancer (NSCLC) showed a ... Seeking Alpha, 48 minutes ago
[x]  

881 images for novartis

World Pharma News, 1 hour ago
yimg.com, 24 minutes ago
Libyan Express, 1 day ago
reutersmedia.net, 13 minutes ago
Investing.com, 30 minutes ago
yimg.com, 24 minutes ago
Yahoo! Finance, 39 minutes ago
reutersmedia.net, 13 minutes ago
SleekMoney, 1 day ago
Yahoo! India, 2 days ago
Pharmaceutical Business Review

Avillion's BOSULIF beats Gleevec in late-stage study in type of leukemia; licensee Pfizer to pursue global registrations to expand label

A Phase 3 study, BFORE, assessing Avillion LLP's BOSULIF (bosutinib) compared to Novartis' (NYSE: NVS ) Gleevec (imatinib mesylate) for the first-line treatment of patients with chronic phase Philadelphia chromosome-positive (Ph+) chronic myeloid ...
 Seeking Alpha23 hours ago Novartis' drug tops chemotherapy in untreated lung cancer patients  Sharenet18 minutes ago Pfizer's Bosulif found superior to Gleevec in phase 3 study in type of leukemia  Pharmaceutical Business Review5 hours ago Pfizer blood cancer drug tops standard therapy for untreated patients  Reuters23 hours ago
[x]  
Libyan Express

An experimental treatment eliminated an aggressive blood cancer in 82% of patients treated (NVS)

(Reuters) - An experimental cancer therapy being developed by Novartis AG eliminated an aggressive form of blood cancer in 82 percent of children and young adults treated with modified immune cells in a mid-stage trial, the company said on Saturday.
 Business Insider23 hours ago Novartis in talks to sell some central nervous system drugs- sources  Sharenet44 minutes ago Novartis says experimental cancer therapy eliminated blood cancer in 82% of patients  Libyan Express1 day ago New therapy promises cancer cure  Financial Express Bangladesh2 days ago
[x]  
Channel NewsAsia

UPDATE 1-Air Berlin gets cash boost with Niki sale to Etihad

Novartis CEO plays down prospects for Actelion bid: Blick VIENNA Novartis Chief Executive Joe Jimenez has played down suggestions the Swiss drugmaker could bid for Swiss biotech group Actelion, which is in talks with U.S. healthcare group Johnson ...
 Reuters UK1 day ago Novartis softens prospects for Actelion bid  Seeking Alpha1 day ago Une offre de Novartis sur Actelion jugée peu probable  4 Traders15 hours ago Novartis CEO plays down prospects for Actelion bid - Blick  Yahoo! Finance2 days ago
[x]  

Opening For Hiring Drive in Gurgaon / Clinical SAS Programmers

Job Description: Novartis Healthcare is hiring …! Job location : Hyderabad. NOTE: We have cancelled the drive in Gurgaon on 09 Dec and calling all the applicants and scheduling telephonic interview primarily and the shortlisted are ...
 Siasat Daily4 hours ago
pharmaphorum

Novartis Makes Its Case For Driving A CAR Into The Real World

Rather like Kite's (NASDAQ: KITE ) registrational Zuma-1 trial of KTE-C19 in lymphoma, Novartis (NYSE: NVS ) Eliana study has generated a fileable response rate. In the case of the Swiss firm's rival CAR-T therapy, CTL019, this is in childhood ...
 Seeking Alpha18 hours ago White gowns, double gloves, and no makeup: inside a CAR-T factory  StatNews.com5 hours ago Spotlight On: Juno gets lapped in CAR-T race as Kite and Novartis vie for finish line  FirstWord Pharma17 hours ago Kite in CAR-T pole position as rolling submission begins  pharmaphorum1 day ago
[x]  

What Smart Money Has To Say About Novartis AG (ADR) (NVS)

More Legendary investors such as Leon Cooperman and Seth Klarman earn enormous amounts of money for themselves and their investors by doing in-depth research on small-cap stocks that big brokerage houses don't publish. Small cap stocks -especially ...
 Yahoo! Finance16 hours ago

Oxford Biomedica: Encouraging Ctl019 Data In Novartis Venture

At ASH (American Society of Hematology) this weekend, Novartis (NYSE:NVS) presented data from its global registration trial (ELIANA) of CTL019 in relapsed/refractory (r/r) paediatric and young adults with B-cell acute lymphoblastic leukaemia ...
 Investing.com4 hours ago Can CAR-T cancer treatments be fine-tuned to avoid toxic side effects?  FierceBiotech22 hours ago Novartis presents results from first global registration trial of CTL019 in pediatric and young adult patients with r/r B-ALL  PR Newswire2 days ago Novartis Presents CTL019 Trial Results In Patients With R/r B-ALL  Nasdaq2 days ago
[x]  
Nasdaq

Novartis: Zykadia More Than Doubles Progression-free Survival In ASCEND-4 Study

Bruno Strigini, CEO, Novartis Oncology , said: "Based on these results, Novartis is initiating discussions with regulatory authorities worldwide regarding this potential use of Zykadia to further improve outcomes for patients with ALK+ advanced ...
 Nasdaq4 hours ago
[x]  

Findings Reported by Novartis on CTL-019 at ASH

 London Stock Exchange1 day ago
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
1.
2.
3.
4.
5.
6.
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts

Get

Realtime News

on your Webpage

Add Widget >Get your members hooked!
    
Alerts
Get updated on latest news & your favorite topics right in your inbox!
 
More     Less